Search results for "antineoplastic"

showing 10 items of 2217 documents

Role of biomarkers in monitoring antiblastic cardiotoxicity

2016

Early detection of anticancer drug-induced cardiotoxicity (CTX) has been evaluated by most international scientific cardiology and oncology societies. High expectations have been placed on the use of specific biomarkers. In recent years, conventional biomarkers and molecules of more recent interest have been tested and compared in the context of anticancer drug-related CTX. Encouraging results were obtained from studies on molecules of myocardial damage, such as troponin and markers of myocardial wall stress, including circulating natriuretic peptides, as well as from the assessment of the products of inflammation or circulating levels of free radicals. However, clear guidelines on their se…

cardiac toxicitymedicine.medical_specialtyantiblasticantineoplasticEarly detectionContext (language use)Antineoplastic Agentsantiblastic; anticancer drugs; antineoplastic; biomarkers; brain natriuretic peptide; cardiac toxicity; troponin; Cardiology and Cardiovascular Medicine030204 cardiovascular system & hematologyBioinformaticsbrain natriuretic peptideSensitivity and Specificity03 medical and health sciencesWall stress0302 clinical medicineCardiac toxicityNeoplasmsNatriuretic Peptide BrainmedicineHumansanticancer drugIntensive care medicineantineoplastic antiblastic anticancer drugs biomarkers brain natriuretic peptide cardiac toxicity troponinMonitoring PhysiologicCardiotoxicitybusiness.industrytroponinbiomarkersGeneral MedicineTime optimalCardiotoxicityanticancer drugsEarly DiagnosisCardiovascular Diseases030220 oncology & carcinogenesisbiomarkerbusinessCardiology and Cardiovascular Medicine
researchProduct

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug …

2016

Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to th…

cardio-oncologymedicine.medical_treatmentCardiomyopathyheart failure030204 cardiovascular system & hematologyanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Anthracyclines; Antibiotics Antineoplastic; Cardiology; Cardiomyopathies; Cardiotoxicity; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Disease Managementanthracyclines; cardiotoxicity; heart failurecardiology consult0302 clinical medicineCardiologistsAntibioticsNeoplasmsDisease management (health)Societies Medicalmedia_commonanthracyclinesAntibiotics AntineoplasticDisease ManagementGeneral MedicineAntineoplasticItalyCardiovascular Diseases030220 oncology & carcinogenesisSupplement SubmissionPractice Guidelines as TopicCardiologyCardiomyopathiesRisk assessmentCardiology and Cardiovascular MedicineDrugmedicine.medical_specialtyAnthracyclinemedia_common.quotation_subjectCardiologycardiotoxicityanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Cardiology and Cardiovascular MedicineAntineoplastic AgentsanthracyclineRisk Assessment03 medical and health sciencesMedicalInternal medicinemedicineHumansIntensive care medicineCardiotoxicityChemotherapybusiness.industrymedicine.diseaseHeart failureSocietiesbusinessJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents

2021

Three novel pyrazolo-[4,3-e][1,2,4]triazolopyrimidine derivatives (1, 2, and 3) were designed, synthesized, and evaluated for their in vitro biological activity. All three compounds exhibited different levels of cytotoxicity against cervical and breast cancer cell lines. However, compound 1 showed the best antiproliferative activity against all tested tumor cell lines, including HCC1937 and HeLa cells, which express high levels of wild-type epidermal growth factor receptor (EGFR). Western blot analyses demonstrated that compound 1 inhibited the activation of EGFR, protein kinase B (Akt), and extracellular signal-regulated kinase (Erk)1/2 in breast and cervical cancer cells at concentrations…

cervical cancercrystal X-ray analysisPharmaceutical ScienceAntineoplastic AgentsArticleAnalytical ChemistryHeLa03 medical and health sciencesbreast cancerQD241-4410302 clinical medicineDrug DiscoveryHumansEpidermal growth factor receptorPhysical and Theoretical Chemistrypyrazolo[124]triazolopyrimidineCytotoxicityProtein Kinase InhibitorsProtein kinase BCell Proliferation030304 developmental biologyMitogen-Activated Protein Kinase 1pyrazolo[124]triazolopyrimidine; EGF-receptor inhibitor; breast cancer; cervical cancer; molecular docking; crystal X-ray analysis0303 health sciencesBinding SitesMitogen-Activated Protein Kinase 3biologyChemistryKinaseOrganic ChemistryBiological activitymolecular dockingTriazolesbiology.organism_classificationMolecular biologyIn vitroErbB ReceptorsMolecular Docking SimulationPyrimidinesChemistry (miscellaneous)Docking (molecular)030220 oncology & carcinogenesisbiology.proteinMolecular MedicineProto-Oncogene Proteins c-aktEGF-receptor inhibitorHeLa CellsProtein BindingMolecules
researchProduct

Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-sp…

2012

Cetuximab is a human/mouse chimeric IgG1 monoclonal antibody (mAb) to epidermal growth factor receptor, approved for colorectal carcinoma treatment in combination with chemotherapy. The immune-mediated effects elicited by its human fraction of crystallization moiety might critically contribute to the overall anti-tumor effectiveness of the antibody. We therefore investigated cetuximab ability to promote colon cancer cell opsonization and phagocytosis by human dendritic cells (DCs) that are subsequently engaged in antigen-cross presentation to cytotoxic T-lymphocyte (CTL) precursors. Human colon cancer cell lines were evaluated for susceptibility to DC-mediated phagocytosis before and after …

cetuximab; chemotherapy; danger signal; cytotoxic-T-lymphocytes; phagocytosisCancer ResearchColorectal cancerSettore MED/06 - Oncologia MedicaAntigen-Presenting CellsAntibodies Monoclonal Humanizedchemotherapydanger signalCross-PrimingAntigenAntigens NeoplasmCell Line TumorAntineoplastic Combined Chemotherapy ProtocolscetuximabHumansMedicineCytotoxic T cellCetuximabbusiness.industrySettore BIO/14Antibodies MonoclonalphagocytosisDendritic CellsDendritic cellmedicine.diseasecytotoxic-T-lymphocytedigestive system diseasesTumor antigenCTL*OncologyColonic NeoplasmsCancer cellImmunologyLeukocytes MononuclearCancer researchbusinessHT29 Cellscytotoxic-T-lymphocytesT-Lymphocytes Cytotoxicmedicine.drug
researchProduct

Bleomycin, a selective inhibitor of DNA-dependent DNA polymerase from oncogenic RNA viruses.

1972

Abstract Bleomycin, an antibiotic, inhibits the DNA-dependent DNA polymerase from Rauscher murine leukemia virus. Higher concentrations of BLM ∗ are required to inhibit it's RNA-dependent DNA polymerase. These inhibition effects of the non-competitive type are not altered by preincubation of the DNA with BLM. Under comparable conditions neither the DNA-dependent DNA polymerase activity from E. coli and mouse liver nor the DNA-dependent RNA polymerase activity from mouse lymphoma cells are affected by BLM.

congenital hereditary and neonatal diseases and abnormalitiesTime FactorsLymphomaDNA polymeraseHepatitis B virus DNA polymeraseUracil NucleotidesDNA polymerase IIBiophysicsRNA-dependent RNA polymeraseCytosine NucleotidesTritiumBiochemistryRauscher VirusCell LineBleomycinMiceEscherichia coliAnimalsMolecular BiologyPolymeraseDNA clampAntibiotics Antineoplasticbiologyurogenital systemnutritional and metabolic diseasesCell BiologyDNAMolecular biologyReverse transcriptaseKineticsReal-time polymerase chain reactionLiverDNA Nucleotidyltransferasesbiology.proteinRNABiochemical and biophysical research communications
researchProduct

WRN protects against topo I but not topo II inhibitors by preventing DNA break formation

2008

The Werner syndrome helicase/3′-exonuclease (WRN) is a major component of the DNA repair and replication machinery. To analyze whether WRN is involved in the repair of topoisomerase-induced DNA damage we utilized U2-OS cells, in which WRN is stably down-regulated (wrn-kd), and the corresponding wild-type cells (wrn-wt). We show that cells not expressing WRN are hypersensitive to the toxic effect of the topoisomerase I inhibitor topotecan, but not to the topoisomerase II inhibitor etoposide. This was shown by mass survival assays, colony formation and induction of apoptosis. Upon topotecan treatment WRN deficient cells showed enhanced DNA replication inhibition and S-phase arrest, whereas af…

congenital hereditary and neonatal diseases and abnormalitiesWerner Syndrome HelicaseDNA RepairCell SurvivalDNA damageDNA repairBlotting WesternApoptosisBone NeoplasmsBiologyTopoisomerase-I InhibitorBiochemistryArticleWerner Syndrome HelicaseColony-Forming Units AssayHistonesTumor Cells CulturedmedicineHumansTopoisomerase II InhibitorsEnzyme InhibitorsRNA Small InterferingeducationMolecular BiologyEtoposideOsteosarcomaeducation.field_of_studyRecQ HelicasesTopoisomeraseCell CycleDNA Breaksnutritional and metabolic diseasesCell BiologyAntineoplastic Agents PhytogenicMolecular biologyDNA Topoisomerases Type IIExodeoxyribonucleasesBromodeoxyuridineDNA Topoisomerases Type IDNA Replication InhibitionCancer researchbiology.proteinTopoisomerase I InhibitorsTopoisomerase-II InhibitorTopotecanCamptothecinmedicine.drugDNA Repair
researchProduct

Gas phase behavior of radical cations of perfluoroalkyl-1,2,4-triazines: an experimental and theoretical study

2009

Electron ionization mass spectrometry and low-energy collision-induced decomposition reactions occurring in a tridimensional ion trap, together with density functional theory (DFT) calculations on neutrals, even- and odd-electron cations, have been used to study the gas-phase ion chemistry of a series of perfluoroalkyl-1,2,4-triazines. Loss of oxygen, due to thermal degradation occurring before ionization, likely involving the hydroxylamino group, has been observed. Compounds having a carbonyl group at position 6 of the triazine ring fragment in the source by elimination of NO followed by HF or CO. The decomposition pathways occurring due to CID experiments have shown interesting features d…

electron ionizationFree RadicalsStereochemistryIonic bondingDFT calculationAntineoplastic AgentsMass spectrometryGas Chromatography-Mass SpectrometryIonradical ionTandem Mass SpectrometryComputational chemistrySpectroscopyElectron ionizationFluorocarbonsMolecular StructureTriazinesChemistryPolyatomic ionSettore CHIM/06 - Chimica OrganicaModels ChemicalRadical ionUnpaired electronDensity functional theorytriazineGasesfluorinated compounds
researchProduct

Cytotoxic effects of individual and combined sterigmatocystin and nivalenol on liver hepatocellular carcinoma cells

2020

Abstract Since humans are exposed to different mycotoxins through daily intake, there is increasing concern about the adverse effects of the interactions between them. Cytotoxicity of sterigmatocystin (STE) and nivalenol (NIV) alone and in combination in human hepatocarcinoma (HepG2) cells was evaluated by MTT assay. Furthermore, ROS production and alteration of ΔΨm as mechanisms of action were assessed. Cells were treated with concentrations ranging from 0.15 to 5 μM for NIV and from 0.78 to 50 μM for STE individually and in binary combinations. The combination ratio between the mixture STE + NIV was 10:1. The IC50 values of NIV ranged from 0.96 to 0.66 μM, whereas no IC50 values were obta…

endocrine systemCarcinoma HepatocellularSterigmatocystinAntineoplastic AgentsPharmacologyToxicology03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyIc50 valuesmedicineHumansCytotoxic T cellMTT assayCytotoxicityMycotoxinAdverse effect030304 developmental biology0303 health sciencesMolecular StructureLiver NeoplasmsDrug SynergismHep G2 Cells04 agricultural and veterinary sciencesGeneral Medicinemedicine.disease040401 food sciencechemistryHepatocellular carcinomaTrichothecenesFood ScienceSterigmatocystinFood and Chemical Toxicology
researchProduct

Genetically engineered V79 Chinese hamster cells metabolically activate the cytostatic drugs cyclophosphamide and ifosfamide.

1990

V79 cells, genetically engineered to express active cytochromes P450IIB1 and P450IA1, were used to study the cytotoxicity and mutagenicity of cyclophosphamide and ifosfamide. Cyclophosphamide, tested up to a concentration of 2 mM, was not cytotoxic in V79 nor in the P450IA1-expressing V79-derived cell line XEM2. Pronounced cytotoxicity was, however, observed in the P450IIB1-expressing V79-derived cell line SD1. Induction of gene mutations (acquisition of 6-thioguanine resistance) was observed in SD1 cells as well, but the effects were weak. Ifosfamide was inactive in V79 cells, but was cytotoxic in SD1 cells. Ifosfamide mustard, an active metabolite of ifosfamide, was equally cytotoxic and …

endocrine systemCyclophosphamideHealth Toxicology and MutagenesisAntineoplastic AgentsPharmacologyChinese hamsterCell LineBiotransformationCricetinaemedicineAnimalsIfosfamideCytotoxicityCyclophosphamideBiotransformationIfosfamidebiologyGenetically engineeredPublic Health Environmental and Occupational Healthfood and beveragesrespiratory systembiology.organism_classificationCell cultureCytostatic drugsGenetic EngineeringResearch Articlemedicine.drugEnvironmental Health Perspectives
researchProduct

Plasticizer extraction of Taxol infusion solution from various infusion devices.

1996

Taxol solution extracts the plasticizer DEHP (di(2-ethylhexyl)phthalate) from polyvinyl chloride (PVC) materials. In order to minimize patient exposure to DEHP, Taxol solutions should be prepared and administered in PVC-free materials. Particulate matter may form in Taxol infusion solution over time, so that in-line filtration with microporous membranes not greater than 0.22 microns is advisable. The purpose of this study was to evaluate the suitability of various administration- and in-line filter-sets for Taxol application. The extent of leached DEHP was determined using a Reversed Phase HPLC assay specific for DEHP. The four tested administration-sets, labeled as PVC-free, were all found…

endocrine systemPaclitaxelDrug StoragePharmaceutical Sciencemacromolecular substancesPharmacyToxicologylaw.inventionchemistry.chemical_compoundlawPlasticizersMicroporous membranesDiethylhexyl PhthalateHumansPharmacology (medical)Infusions IntravenousFiltrationChromatography High Pressure LiquidDrug PackagingPharmacologyChromatographyInfusion solutionorganic chemicalsExtraction (chemistry)PhthalatePlasticizerGeneral MedicineReversed-phase chromatographyAntineoplastic Agents PhytogenicPolyvinyl chloridechemistryPharmacy worldscience : PWS
researchProduct